http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BE-1001233-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b81c3ecc9a3bd192c754216816991d8a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-20 |
| filingDate | 1987-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1989-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09904422d07cde2c78d3d5a92757b455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23392b8fcbfda01fd49f24380c25108e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5190500d70aa3447c3c794286a1c6c28 |
| publicationDate | 1989-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BE-1001233-A3 |
| titleOfInvention | Use of compounds of the series and isoretuline retuline as pharmaceutical active compounds in particular drugs analgesics, and antiinflammatory antispasmodics. |
| abstract | Compounds with pharmaceutical effect corresponding to the general formula in which in position 16, either R1 or R2 must represent hydrogen while that of the substituents R1 or R2 which does not represent hydrogen represents -CH2OH- or -CH2OH acylated, of preferably acetylated or an aldehyde function; R3 in position 1 represents an alkyl residue or an acyl residue, preferably an acetyl residue; R4 at position 18 represents an alkyl chain, preferably methyl, an acylated -CH2OH- group or preferably acetylated -CH2OH; R5 represents hydrogen or a substituent on the benzene ring. The compounds have an anti-inflammatory effect, an analgesic effect and an antispasmodic effect. |
| priorityDate | 1987-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.